Journal article
Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder
Abstract
OBJECTIVE: This clinical trial evaluated luteal phase dosing with paroxetine controlled release (CR) (12.5 mg and 25 mg) in the treatment of premenstrual dysphoric disorder (PMDD).
STUDY DESIGN: A multicenter, randomized, double-blind, placebo-controlled, 3-arm, fixed-dose study of luteal phase dosing with paroxetine CR in the treatment of PMDD. Three hundred seventy-three patients with PMDD were randomly assigned into the study. The primary …
Authors
Steiner M; Hirschberg AL; Bergeron R; Holland F; Gee MD; Van Erp E
Journal
American Journal of Obstetrics and Gynecology, Vol. 193, No. 2, pp. 352–360
Publisher
Elsevier
Publication Date
August 2005
DOI
10.1016/j.ajog.2005.01.021
ISSN
0002-9378